Date: 8th April 2015

Minutes: Final

Guideline Development Group Meeting 13   Type 2 Diabetes
Place:  NICE Offices & City Tower, Piccadilly Plaza, Manchester, M1 4BT

Present:  Damien Longson (Chair)
          Ian Lewin (IL)
          Sailesh Sankar (SS)
          Jonathan Roddick (JR) – attended from 2:15 – 3pm via teleconference
          Prunella Neale (PN)
          Anne Bentley (AB)
          Amanda Adler (AA) – attended from 2pm via teleconference
          Natasha Jacques (NJ)
          Andrew Farmer (AFr)
          Yvonne Johns (YJ)
          Natasha Marsland (NM)
          Maria Cowell (MC)

Apologies:  Jonathan Roddick (JR)
            Amanda Adler (AA)

In attendance:

NICE Staff:

Sharlene Ting (ST)
Stephanie Mills (SM)
Steven Ward (SWard)
Hugh McGuire (HM)
Clifford Middleton (CM)
Susan Ellerby (SE)
Sue Spiers (SS)
Sarah Palombella (SP)
Phil Alderson (PA) – attended from 9:30 -10am

Observers:
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erin Whittingham</td>
<td>NICE observer (Public Involvement Programme)</td>
</tr>
<tr>
<td>Katie Wyatt</td>
<td>NICE Observer (Implementation)</td>
</tr>
<tr>
<td>John Davidson</td>
<td>NICE Observer (Press Office)</td>
</tr>
<tr>
<td>Kate Moring</td>
<td>NICE Observer (Costing)</td>
</tr>
<tr>
<td>Jonathan Underhill</td>
<td>NICE Observer (Medicines and Prescribing)</td>
</tr>
</tbody>
</table>

1. DL welcomed the group to the 13th meeting of this guideline development group (GDG). This meeting was set up to address feedback from stakeholders post guideline consultation. Apologies were received from AA and JR. All committee members declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in the development of this guideline beyond those which had previously been declared.

   DL asked whether the group agreed that the minutes of the previous meeting were a clear and accurate record. The minutes were agreed by all present. DL gave an overview of the meeting before handing over to PA who wanted to talk to the committee about the NICE commissioning team view on consultation feedback.

2. PA explained that the volume of feedback from stakeholders was significant and there was real consistency in the type of feedback which was received about pharmacological management of type 2 diabetes. PA indicated that revisions to the guideline would be needed before it could be supported by the NICE commissioning team through the guideline validation process.

3. ST presented feedback on target values for HbA1c. The committee considered the comments from stakeholders and how this may impact on the wording of the recommendations and the targets which has been set out in the consultation draft of the guideline.

4. ST presented feedback on the recommendations for self-monitoring of blood glucose levels. Overall feedback in this area had been positive but further clarification of when short term self-monitoring in people with type 2 diabetes was considered by the committee.

   Feedback on anti-platelet therapy was discussed with the committee. The group talked about the evidence underpinning these recommendations and whether the recommendations should be tweaked.

   SM presented a query on erectile dysfunction to the committee. The group felt that no changes to the recommendations were needed. SM also asked the group whether they would like to have explicit cross referral recommendations to areas such as obesity, smoking and physical activity.

5. Following lunch, ST gave an overview of the evidence on pharmacological management in type 2 diabetes to remind the committee of the results of the clinical analyses.
6. The committee discussed the feedback received on the current recommendations for pharmacological management and how the recommendations may need to be altered. The group recognised the concerns of stakeholders and also felt that the algorithm was too complex for healthcare professionals to follow in practice.

The committee went through the recommendations for each stage of treatment debating the issues of stopping rules for therapy, appropriate treatment for those in whom metformin is contraindicated or not tolerated and how to simplify the treatment pathway.

It was not possible to finish all the work on this section of the guideline in light of the level of stakeholder feedback so it was agreed to call an additional meeting as soon as possible to continue committee discussions. SM confirmed she would be in touch with the committee as soon as possible about an appropriate date.

**Date, time and venue of the next meeting**

Meeting will start at 10am on 16th April 2015 in Manchester.